FindTrial
Sign In

Glumetinib Tablets

DRUG3 trials

Sponsors

CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Shanghai JMT-Bio Inc.

Conditions

Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma and Other Solid TumorsLocally Advanced/Recurrent or Distant Metastasized Non-small Cell Lung Cancer With MET OverexpressionRecurrent or Metastatic NSCLC Patients With Classical EGFR Mutations Accompanied by MET Amplification or Overexpression

Phase 2

A Study to Evaluate the Efficacy and Safety of the Combination of Glumetinib and Docetaxel（Albumin Bound）Verse Docetaxel for the Treatment of MET-overexpressed Non-small Cell Lung Cancer
Not yet recruitingNCT06525350
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Locally Advanced/Recurrent or Distant Metastasized Non-small Cell Lung Cancer With MET Overexpression
Start: 2024-07-31End: 2028-06-25Target: 256Updated: 2024-07-29
Glumetinib Combined With Osimertinib Treatment for Non-Small Cell Lung Cancer Patients
Not yet recruitingNCT06908772
Shanghai JMT-Bio Inc.Recurrent or Metastatic NSCLC Patients With Classical EGFR Mutations Accompanied by MET Amplification or Overexpression
Start: 2025-04-01End: 2030-01-31Target: 390Updated: 2025-04-03
Safety and Efficacy of Glumetinib Combined With Docetaxel for Injection (Albumin-bound) in Patients With Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma and Other Solid Tumors
RecruitingNCT06947291
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma and Other Solid Tumors
Start: 2025-06-04End: 2027-10-30Target: 350Updated: 2025-09-08